|Toxiciy Grade:||4||City/State/Province:||Bethesda, Maryland|
|Treatments:||Biologic therapy||Hospital:||National Cancer Institute|
Patients: This phase II study involved 24 women with recurrent epithelial ovarian cancer with a median age of 53, ranging from 33-67. Of these, 16 completed the treatment and were evaluated by the researchers.
Treatment: These women were treated with gefitinib (Iressa), a small molecule that inhibits the epidermal growth factor receptor.
Toxicity: Grade 4 toxicities were experienced by two women: one had hyponatremia and another hemorrhaged due to her spleen rupturing. Grade 3 toxicities were abdominal pain, diarrhea, and an abnormal lab result. Grade 2 toxicities included anorexia, diarrhea, nausea, vomiting, fatigue, weight loss, and skin changes.
Results: There were no complete or partial responses. Nine patients had stable disease for more than two months. Median survival times were not reported.
Correspondence: Elise C. Kohn, M.D.